In the cohort with previously untreated patients with NSCLC without EGFR/ALK alterations (cohort 1), patients with squamous histology experienced a 75% ORR with a median DOR of 15.4 months and 95% DCR, and the 9-month PFS and OS rates were 67% and 93%, respectively. This evidence concerns the gene ALK and non-small cell lung carcinoma.